GSTZ1

Across TCGA pan-cancer cohorts, GSTZ1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSTZ1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GSTZ1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTZ1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where GSTZ1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.475	0.302	.003	18	view →
UCEC	DFS	Quartile	All	0.963	0.726	.014	16	view →
LSCC	OS	Tertile	II,III,IV	1.000	0.665	.006	12	view →
CCRCC	OS	Median	All	0.994	0.894	.027	10	view →
LUAD	DFS	Tertile	All	1.000	0.670	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GSTZ1–PDAC (DFS)

Open the PDAC breakdown →